Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Go back to Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
(NASDAQ: ACOG) Delayed: 9.04 +0.06 (0.67%)
Previous Close $8.98    52 Week High $ 
Open $8.95    52 Week Low $ 
Day High $9.37    P/E N/A 
Day Low $8.90    EPS $ 
Volume 40,376